Loading company…
SeaBeLife develops candidate compounds targeting regulated cell death and related diseases.
SeaBeLife develops compounds targeting necroptosis and ferroptosis, forms of regulated cell death associated with organ damage and disease. Its research includes acute liver and kidney conditions and degenerative and ocular disorders. Founded in 2019, it is based in Roscoff, France. In October 2025, it raised EUR 2 million in pre-Series A funding led by iXLife Capital, with INEXT and Femmes Business Angels participating, to develop treatments for dry age-related macular degeneration and severe acute hepatitis.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in